Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.
Key PointsThe key to the company's future is medical insurers adopting Galleri.
Grail (NASDAQ: GRAL) stock has surged by 180% over the past six months following a positive Food and Drug Administration (FDA) Advisory Committee vote on its multi-cancer early detection test (MCED), Galleri. This represents a remarkable turnaround for the stock, which experienced a significant drop in February after reporting top-line results from a pivotal Galleri trial that fell short of its primary objective.
The Galleri test is already being utilized, with its availability on an out-of-pocket basis allowing patients to directly pay for the test. However, sales are expected to expand significantly once medical insurers begin covering the test. While FDA approval is not mandatory for insurers to cover the test, it is generally a prerequisite for widespread adoption. Moreover, Grail must successfully demonstrate the efficacy and cost-effectiveness of the test to convince insurers of its value.
As the stock continues to gain momentum, Grail appears to have substantial room for further growth.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
